Medical News

RSS

Hawthorn announces licensing deal with University of Pittsburgh for novel monoclonal antibodies for cancer

Hawthorn Pharmaceuticals, Inc. today announced a global licensing deal with the University of Pittsburgh covering a series of novel monoclonal antibodies for cancer. The antibody portfolio targets a variety of cancers through the cell surface chondrotin sulfate proteoglycan 4 (CSPG4), which plays an important role in signaling pathways regulating tumor cell survival, growth, and motility.

17 May 2010

Health law's affect on ERs, doctors' panel, young adults examined

Officials and stakeholders are examining the new health reform law for changes that the reform will mean for their organizations and industries.

17 May 2010

BaroFold licenses PreEMT Technology to Nuron Biotech for development of BaroFeron

BaroFold, Inc. today announced that it has entered into an agreement to exclusively license its PreEMT™ Technology to Nuron Biotech for the development of BaroFeron™ and follow-on interferon beta products. BaroFeron is a proprietary recombinant human interferon beta being developed for the treatment of multiple sclerosis. Specific terms of the agreement are not disclosed.

17 May 2010

Health Robotics re-acquires European rights for CytoCare from B. Braun

Health Robotics and B. Braun Melsungen AG today announced that in exchange for undisclosed consideration, Health Robotics has re-acquired from B. Braun the exclusive marketing, sales, installation, implementation, interface, manufacturing, and technical support European rights for CytoCare, a robot designed to manufacture chemotherapy and hazardous IV Admixtures, and which rights B. Braun had previously acquired from Health Robotics in 2007 and 2008.

From B. Braun Melsungen AG 17 May 2010

Today's Opinions and Editorials: Support for Berwick and health reform's next tests

He is well-qualified to make the many crucial decisions surrounding Medicare and Medicaid, and could end up being one of the most significant appointees in the administration (5/17).

17 May 2010

Mpex Pharmaceuticals presents Phase 2b trial results of Aeroquin for cystic fibrosis at ATS Annual Meeting

Mpex Pharmaceuticals, Inc. today announced the presentation of data from its Phase 2b clinical trial with Aeroquin™ (a proprietary aerosol formulation of levofloxacin, MP-376) in cystic fibrosis (CF) at the American Thoracic Society (ATS) Annual Meeting in New Orleans.

17 May 2010

Hospitals to get more bargaining clout for medical devices

The Wall Street Journal: "Hospitals lack leverage when negotiating prices for high-cost implants like defibrillators and replacement hips because individual doctors, rather than hospitals, typically select the products they use in their patients. Since these doctors often aren't hospital employees, they have little incentive to bargain-hunt.

17 May 2010

Dehaier Medical Systems becomes exclusive China distributor of Welch Allyn's patient monitors

Dehaier Medical Systems Ltd., an emerging leader in the development, assembly, marketing and sale of medical products in China, said today that it has become the exclusive China distributor of Welch Allyn's patient monitors.

17 May 2010

IRS to announce tax credit rules for small business health premiums

The Associated Press: "Pitching President Barack Obama's health care law to skeptical business owners, the IRS on Monday will announce ground rules for small firms wishing to claim a new federal tax credit for health insurance." The tax credit, which was created by the new health overhaul law, "covers up to 35 percent of the premiums that certain small businesses pay on behalf of their workers.

17 May 2010

Del Global Technologies files registration statement with SEC for rights offering

Del Global Technologies Corp. today announced that it filed a registration statement on Form S-1 with the Securities and Exchange Commission (the "SEC") for a rights offering to its existing shareholders. The rights offering will be made through the distribution of non-transferable subscription rights to purchase shares of the Company's common stock, par value $0.10 per share, at a subscription price to be determined.

17 May 2010

Dartmouth to start health care delivery research center

"Dartmouth College is getting $35 million to open a center it hopes will help the nation take the next big steps in health care reform: improving quality while lowering costs," The Associated Press reports.

17 May 2010

Aastrom Biosciences initiates treatment in Phase 2 catheter-based clinical trial for dilated cardiomyopathy

Aastrom Biosciences, Inc., the leading developer of autologous cellular therapies for the treatment of severe cardiovascular diseases, today announced that the first patient has been treated in the company's U.S. Phase 2 catheter-based clinical trial to treat dilated cardiomyopathy (DCM). Treatment was performed by interventional cardiologist Timothy D. Henry, M.D., FACC, at the Minneapolis Heart Institute® at Abbott Northwestern Hospital in Minneapolis, MN.

17 May 2010

Emisphere Technologies first-quarter net loss increases to $18.5 million

Emisphere Technologies, Inc. today announced its financial results for the first quarter 2010.

17 May 2010

FDA grants NeoPharm's IL13-PE38QQR orphan-drug designation for treatment of IPF

NeoPharm, Inc., announced today that the Office of Orphan Products Development of the United States Food and Drug Administration (FDA) has granted orphan-drug designation for IL13-PE38QQR (IL13-PE) for the treatment of Idiopathic Pulmonary Fibrosis (IPF).

17 May 2010

Communication Intelligence first-quarter total revenue decreases to $207,000

Communication Intelligence Corporation, a leading supplier of electronic signature solutions for business process automation in the financial industry and the recognized leader in biometric signature verification, announced today its financial results for the first quarter ended March 31, 2010.

17 May 2010

Argos Therapeutics presents AGS-004 autologous dendritic cell therapy Phase 2a trial data at 19th CAHR

Argos Therapeutics today announced the presentation of data from the Phase 2a trial of AGS-004, demonstrating that the personalized immunotherapy has a positive impact on the genetic diversity of residual HIV virus, and also results in substantially increased time to viral rebound in HIV patients treated with AGS-004 following antiretroviral therapy (ART) interruption.

17 May 2010

TriReme Medical receives FDA expanded clearance for GliderXtreme PTA balloon catheter

TriReme Medical, Inc. (TMI) announced today that it has received FDA clearance for an expanded matrix of sizes for its GliderXtreme™ PTA balloon catheter. GliderXtreme™ is now approved for the percutaneous transluminal treatment of lesions in the peripheral vasculature in balloon diameters from 2.0 – 5.0mm and in balloon lengths up to 200mm.

17 May 2010

FDA approves ROXRO PHARMA's SPRIX Nasal Spray

ROXRO PHARMA, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved SPRIX™ (ketorolac tromethamine) Nasal Spray, for the short-term (up to 5 days) management of acute moderate to moderately severe pain that requires analgesia at the opioid level.

17 May 2010

Cortex first-quarter net income increases to $0.08 per share

Cortex Pharmaceuticals, Inc. reported net income of approximately $5,596,000, or $0.08 per share for the quarter ended March 31, 2010 compared with a net loss of $3,168,000, or $0.07 per share for the corresponding prior year period, with the difference reflecting revenues from the Company's March 2010 transaction with Biovail Laboratories International SRL (Biovail).

17 May 2010

Hemispherx Biopharma to conduct study of Ampligen antiviral in China

As part of its expanding international program Hemispherx Biopharma, Inc., announced an agreement with Fountain Medical Development Ltd., a leading Chinese clinical research organization (CRO) to prepare, file and gain approval from the authorities in China to conduct a study of Ampligen, an investigational therapeutic.

17 May 2010

Medical News

Hawthorn announces licensing deal with University of Pittsburgh for novel monoclonal antibodies for cancer

Health law's affect on ERs, doctors' panel, young adults examined

BaroFold licenses PreEMT Technology to Nuron Biotech for development of BaroFeron

Health Robotics re-acquires European rights for CytoCare from B. Braun

Today's Opinions and Editorials: Support for Berwick and health reform's next tests

Mpex Pharmaceuticals presents Phase 2b trial results of Aeroquin for cystic fibrosis at ATS Annual Meeting

Hospitals to get more bargaining clout for medical devices

Dehaier Medical Systems becomes exclusive China distributor of Welch Allyn's patient monitors

IRS to announce tax credit rules for small business health premiums

Del Global Technologies files registration statement with SEC for rights offering

Dartmouth to start health care delivery research center

Aastrom Biosciences initiates treatment in Phase 2 catheter-based clinical trial for dilated cardiomyopathy

Emisphere Technologies first-quarter net loss increases to $18.5 million

FDA grants NeoPharm's IL13-PE38QQR orphan-drug designation for treatment of IPF

Communication Intelligence first-quarter total revenue decreases to $207,000

Argos Therapeutics presents AGS-004 autologous dendritic cell therapy Phase 2a trial data at 19th CAHR

TriReme Medical receives FDA expanded clearance for GliderXtreme PTA balloon catheter

FDA approves ROXRO PHARMA's SPRIX Nasal Spray

Cortex first-quarter net income increases to $0.08 per share

Hemispherx Biopharma to conduct study of Ampligen antiviral in China

Evolving spectrophotometry for modern biopharma workflows

Scaling B-cell cloning workflows for antibody development

Fluidics in Modern Healthcare & Medical Device Innovation

Latest News